Oral LD50 in rat and mouse is 3550 mg/kg and 730 mg/kg, respectively. Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. In children, stimulation predominates initially in a syndrome which may include excitement, hallucinations, ataxia, incoordination, muscle twitching, athetosis, hyperthermia, cyanosis convulsions, tremors, and hyperreflexia followed by postictal depression and cardio-respiratory arrest. Convulsions in children may be preceded by mild depression. Dry mouth, fixed dilated pupils, flushing of the face, and fever are common. In adults, CNS depression, ranging from drowsiness to coma, is more common.
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Clemastine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clemastine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Clemastine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Clemastine. |
| Hydrocodone | Clemastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Clemastine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Clemastine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Clemastine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clemastine. |
| Mirtazapine | Clemastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Clemastine. |
| Orphenadrine | Clemastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Clemastine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Clemastine. |
| Pramipexole | Clemastine may increase the sedative activities of Pramipexole. |
| Ropinirole | Clemastine may increase the sedative activities of Ropinirole. |
| Rotigotine | Clemastine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Clemastine. |
| Sodium oxybate | Clemastine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Clemastine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Clemastine. |
| Thalidomide | Clemastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Clemastine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Benzylpenicilloyl polylysine | Clemastine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Clemastine. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Clemastine. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Clemastine. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clemastine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Clemastine. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Clemastine. |
| Linezolid | Linezolid may increase the anticholinergic activities of Clemastine. |
| Furazolidone | Furazolidone may increase the anticholinergic activities of Clemastine. |
| Procaine | Procaine may increase the anticholinergic activities of Clemastine. |
| Tranylcypromine | Tranylcypromine may increase the anticholinergic activities of Clemastine. |
| Phenelzine | Phenelzine may increase the anticholinergic activities of Clemastine. |
| Minaprine | Minaprine may increase the anticholinergic activities of Clemastine. |
| Selegiline | Selegiline may increase the anticholinergic activities of Clemastine. |
| Procarbazine | Procarbazine may increase the anticholinergic activities of Clemastine. |
| Moclobemide | Moclobemide may increase the anticholinergic activities of Clemastine. |
| Isocarboxazid | Isocarboxazid may increase the anticholinergic activities of Clemastine. |
| Rasagiline | Rasagiline may increase the anticholinergic activities of Clemastine. |
| Pargyline | Pargyline may increase the anticholinergic activities of Clemastine. |
| Clorgiline | Clorgiline may increase the anticholinergic activities of Clemastine. |
| Iproniazid | Iproniazid may increase the anticholinergic activities of Clemastine. |
| Nialamide | Nialamide may increase the anticholinergic activities of Clemastine. |
| Safinamide | Safinamide may increase the anticholinergic activities of Clemastine. |
| 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Clemastine. |
| Methylene blue | Methylene blue may increase the anticholinergic activities of Clemastine. |
| Hydracarbazine | Hydracarbazine may increase the anticholinergic activities of Clemastine. |
| Pirlindole | Pirlindole may increase the anticholinergic activities of Clemastine. |
| Toloxatone | Toloxatone may increase the anticholinergic activities of Clemastine. |
| Benmoxin | Benmoxin may increase the anticholinergic activities of Clemastine. |
| Mebanazine | Mebanazine may increase the anticholinergic activities of Clemastine. |
| Octamoxin | Octamoxin may increase the anticholinergic activities of Clemastine. |
| Pheniprazine | Pheniprazine may increase the anticholinergic activities of Clemastine. |
| Phenoxypropazine | Phenoxypropazine may increase the anticholinergic activities of Clemastine. |
| Pivhydrazine | Pivhydrazine may increase the anticholinergic activities of Clemastine. |
| Safrazine | Safrazine may increase the anticholinergic activities of Clemastine. |
| Caroxazone | Caroxazone may increase the anticholinergic activities of Clemastine. |
| Harmaline | Harmaline may increase the anticholinergic activities of Clemastine. |
| Brofaromine | Brofaromine may increase the anticholinergic activities of Clemastine. |
| Ethanol | Clemastine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Clemastine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Clemastine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Clemastine is combined with Fluvoxamine. |
| Duloxetine | The risk or severity of adverse effects can be increased when Clemastine is combined with Duloxetine. |
| Sibutramine | The risk or severity of adverse effects can be increased when Clemastine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Clemastine is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when Clemastine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Clemastine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Clemastine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Clemastine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Clemastine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Clemastine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Clemastine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Clemastine is combined with Alaproclate. |
| Paroxetine | The risk or severity of adverse effects can be increased when Clemastine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Clemastine is combined with Sertraline. |
| Phentermine | Phentermine may decrease the sedative activities of Clemastine. |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of Clemastine. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Clemastine. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Clemastine. |
| Lisdexamfetamine | The serum concentration of dextroamphetamine, an active metabolite of Lisdexamfetamine, can be increased when used in combination with Clemastine. |
| Mephentermine | Mephentermine may decrease the sedative activities of Clemastine. |
| MMDA | MMDA may decrease the sedative activities of Clemastine. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Clemastine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Clemastine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Clemastine. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Clemastine. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Clemastine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Clemastine. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Clemastine. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Clemastine. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Clemastine. |
| Ritobegron | Ritobegron may decrease the sedative activities of Clemastine. |
| Mephedrone | Mephedrone may decrease the sedative activities of Clemastine. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Clemastine. |
| Gepefrine | Gepefrine may decrease the sedative activities of Clemastine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Clemastine. |
| Amphetamine | Amphetamine may decrease the sedative activities of Clemastine. |